FTC Sues Drugmakers for Delaying Generic AndroGel

The FTC and the state of California are suing four drugmakers, contending they delayed the introduction of generic versions of Solvay Pharmaceuticals’ AndroGel testosterone-replacement drug. Watson Pharmaceuticals and Par Pharmaceutical “agreed to share in Solvay’s monopoly profits, abandon their patent challenges, and refrain from competing with low-cost generic” versions of AndroGel (testosterone) for nine years, according to an antitrust lawsuit filed last week in the U.S. District Court for the Central District of California. The fourth drugmaker involved is Paddock Laboratories.
Drug Industry Daily